Increased CD19+CD24+CD27+ B regulatory cells are associated with insulin resistance in patients with type I Hashimoto's thyroiditis

Yang,Min; Du,Changji; Wang,Yinping; Liu,Jun

doi:10.3892/mmr.2017.6507

Increased CD19+CD24+CD27+ B regulatory cells are associated with insulin resistance in patients with type I Hashimoto's thyroiditis

Authors:
- Min Yang
- Changji Du
- Yinping Wang
- Jun Liu
View Affiliations

Affiliations: Department of Endocrinology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, P.R. China, Department of Clinical Lab, The Daopei Hospital of Shanghai, Shanghai 200240, P.R. China
Published online on: April 25, 2017 https://doi.org/10.3892/mmr.2017.6507
Pages: 4338-4345

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hashimoto's thyroiditis (HT) is characterized by dysregulated immune responses and is commonly associated with insulin resistance. However, the mechanism of insulin resistance in HT remains to be fully elucidated. The aim of the present study was to investigate the correlation between the percentage of B regulatory lymphocytes (Bregs) and insulin resistance in patients with HT but with normal thyroid function (type I). A total of 59 patients with type I HT and 38 healthy volunteers were enrolled in the study. An oral glucose tolerance test was performed to measure insulin secretion and assess β‑cell functions. Flow cytometry was performed to examine the percentages of lymphocyte populations. The patients with HT exhibited normal fasting and postprandial glucose and fasting insulin secretion, but increased secretion of early‑phase and total insulin. The patients with HT also had insufficient β‑cell compensation for insulin resistance, indicated by a reduced disposition index, in the fasting state. An elevation in the percentage of CD19+CD24+CD27+ Bregs was also observed, which correlated positively with insulin secretion and insulin resistance in the fasting state. The patients with type I HT had postprandial insulin resistance and insufficient β‑cell compensation for fasting insulin resistance. Therefore, the increase in CD19+CD24+CD27+ Bregs was closely associated with fasting insulin secretion. These results provide novel insight into the mechanism of insulin resistance in HT.

View Figures

View References

1	Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppa M, Alevizaki M, Mitrou P, Lambadiari V, Boutati E, Nikzas D, et al: Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 160:785–790. 2009. View Article : Google Scholar
2	Fernandez-Real JM, Lopez-Bermejo A, Castro A, Casamitjana R and Ricart W: Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjects. J Clin Endocrinol Metab. 91:3337–3343. 2006. View Article : Google Scholar
3	Roos A, Bakker SJ, Links TP, Gans RO and Wolffenbuttel BH: Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab. 92:491–496. 2007. View Article : Google Scholar
4	Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Panagiotakos DB, Koukkou E, Tzanela M, Thalassinos N and Raptis SA: Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab. 91:4930–4937. 2006. View Article : Google Scholar
5	Jornayvaz FR, Lee HY, Jurczak MJ, Alves TC, Guebre-Egziabher F, Guigni BA, Zhang D, Samuel VT, Silva JE and Shulman GI: Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology. 153:583–591. 2012. View Article : Google Scholar
6	Stanická S, Vondra K, Pelikánová T, Vlcek P, Hill M and Zamrazil V: Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. Clin Chem Lab Med. 43:715–720. 2005. View Article : Google Scholar
7	Handisurya A, Pacini G, Tura A, Gessl A and Kautzky-Willer A: Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). Clin Endocrinol (Oxf). 69:963–969. 2008. View Article : Google Scholar
8	Dessein PH, Joffe BI and Stanwix AE: Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. Thyroid. 14:443–446. 2004. View Article : Google Scholar
9	Finucane JF: Carbohydrate tolerance in autoimmune thyroiditis. Diabetes. 24:829–832. 1975. View Article : Google Scholar
10	Kornete M, Mason ES and Piccirillo CA: Immune regulation in T1D and T2D: Prospective role of foxp3+ treg cells in disease pathogenesis and treatment. Front Endocrinol (Lausanne). 4:762013.
11	Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA and Bluestone JA: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 346:1692–1698. 2002. View Article : Google Scholar
12	Penaranda C, Tang Q and Bluestone JA: Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol. 187:2015–2022. 2011. View Article : Google Scholar :
13	Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, et al: Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 132:166–173. 2009. View Article : Google Scholar :
14	Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, et al: Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 361:2143–2152. 2009. View Article : Google Scholar
15	Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, et al: B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med. 17:610–617. 2011. View Article : Google Scholar :
16	Filaci G, Fravega M, Negrini S, Procopio F, Fenoglio D, Rizzi M, Brenci S, Contini P, Olive D, Ghio M, et al: Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol. 65:142–156. 2004. View Article : Google Scholar
17	Yang M, Rui K, Wang S and Lu L: Regulatory B cells in autoimmune diseases. Cell Mol Immunol. 10:122–132. 2013. View Article : Google Scholar :
18	Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS and Bhan AK: Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 16:219–230. 2002. View Article : Google Scholar
19	Mizoguchi A and Bhan AK: A case for regulatory B cells. J Immunol. 176:705–710. 2006. View Article : Google Scholar
20	Kalampokis I, Yoshizaki A and Tedder TF: IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 15 Suppl 1:S12013. View Article : Google Scholar :
21	Shi L, Bi M, Yang R, Zhou J, Zhao S, Fan C, Shan Z, Li Y and Teng W: Defective expression of regulatory B cells in iodine-induced autoimmune thyroiditis in non-obese diabetic H-2(h4) mice. J Endocrinol Invest. 37:43–50. 2014. View Article : Google Scholar
22	Lin Y and Sun Z: Thyroid hormone potentiates insulin signaling and attenuates hyperglycemia and insulin resistance in a mouse model of type 2 diabetes. Br J Pharmacol. 162:597–610. 2011. View Article : Google Scholar :
23	Slatosky J, Shipton B and Wahba H: Thyroiditis: Differential diagnosis and management. Am Fam Physician. 61:1047–1052, 1054. 2000.
24	Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part. 1:Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553. 1998.
25	Samuel VT and Shulman GI: Mechanisms for insulin resistance: Common threads and missing links. Cell. 148:852–871. 2012. View Article : Google Scholar :
26	Bergman RN, Ader M, Huecking K and Van Citters G: Accurate assessment of beta-cell function: The hyperbolic correction. Diabetes. 51 Suppl 1:S212–S220. 2002. View Article : Google Scholar
27	Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, et al: T-lymphocyte infiltration in visceral adipose tissue: A primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol. 28:1304–1310. 2008. View Article : Google Scholar
28	Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 27:813–823. 2004. View Article : Google Scholar
29	Jagannathan M, McDonnell M, Liang Y, Hasturk H, Hetzel J, Rubin D, Kantarci A, Van Dyke TE, Ganley-Leal LM and Nikolajczyk BS: Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia. 53:1461–1471. 2010. View Article : Google Scholar :
30	DeFuria J, Belkina AC, Jagannathan-Bogdan M, Snyder-Cappione J, Carr JD, Nersesova YR, Markham D, Strissel KJ, Watkins AA, Zhu M, et al: B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci USA. 110:pp. 5133–5138. 2013; View Article : Google Scholar :